Twist1 Regulates the Immune Checkpoint VISTA and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells
Journal of Cellular and Molecular Medicine · 2025-05 · 29 (9)
DOI: 10.1111/jcmm.70586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 08.05.2025. Verfasst von Kubra Sena Bas Topcu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Science, Bartin University, Bartin, Türkiye. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Twist-Related Protein 1, Nuclear Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Scientific and Technological Research Council of Türkiye (TUBITAK).
Abstract (Originalsprache)
Pancreatic cancer is one of the deadliest malignant tumours worldwide. Despite the developments in the treatments of pancreatic cancer, survival rates remain at a low level, and the mechanisms underlying the aggressive course of the cancer are not fully understood. VISTA is an immune checkpoint and has recently become a significant target in cancer treatment; however, the roles of VISTA in the development of pancreatic cancer have largely remained unknown. Histone deacetylase inhibitors (HDACi) have been reported to reverse the epithelial‐mesenchymal transition (EMT) and may enhance the efficacy of anti‐PD‐1 therapy. The PD‐L1/PD‐1 immune checkpoint targeted by this therapy shares structural similarity with VISTA. Moreover, combination therapy of vorinostat and anti‐PD‐1 has been shown to significantly reduce tumour growth by suppressing the transcription factor c‐Myc. Therefore, in this study, we aim to investigate the genes that are associated with EMT and explore the potential mechanism involving Twist1, a proto‐oncogene, and VISTA in pancreatic cancer. We also sought to determine the synergistic effects of an HDACi, vorinostat, in combination with Twist1‐siRNA on VISTA expression in pancreatic cancer cells’ viability and proliferation. Our results revealed that Twist1 blockade in combination with vorinostat in pancreatic cancer cells suppresses EMT‐associated genes and the immune checkpoint VISTA compared to treatments administered alone. As a result, identifying the genes associated with EMT in pancreatic cancer and understanding the role of Twist1 in this process is a crucial step to contribute to the identification of new targets for pancreatic cancer treatment and the improvement of existing treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Science, Bartin University, Bartin, Türkiye.
- Department of Molecular Biology and Genetics, Faculty of art and Science, Tokat Gaziosmanpasa University, Tokat, Türkiye.
ORCID-Profile: Ercan Cacan
Förderung
- The Scientific and Technological Research Council of Türkiye (TUBITAK)
Zitieren
APA
Topcu, K. S. B., & Cacan, E. (2025). Twist1 Regulates the Immune Checkpoint VISTA and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells. Journal of Cellular and Molecular Medicine, 29(9). https://doi.org/10.1111/jcmm.70586
Vancouver
Topcu KSB, Cacan E. Twist1 Regulates the Immune Checkpoint VISTA and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells. Journal of Cellular and Molecular Medicine. 2025;29(9). doi:10.1111/jcmm.70586
BibTeX
@article{Topcu2025,
author = {Topcu, Kubra Sena Bas and Cacan, Ercan},
title = {Twist1 Regulates the Immune Checkpoint VISTA and Promotes the Proliferation, Migration and Progression of Pancreatic Cancer Cells},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {9},
doi = {10.1111/jcmm.70586}
}
EUVIMED